Monitor for updates on the strategic alternatives process, as the company's path forward remains uncertain despite clinical progress. The lack of revenue and limited cash raise significant going-concern risks.
Price Chart
Executive Summary
ENDRA Life Sciences reported Q4 and full-year 2025 financial results with a net loss of $7.0 million for the year, down from $11.5 million in 2024, driven by reduced operating expenses. The company also announced it has initiated a strategic alternatives review process while continuing clinical progress on its TAEUS Liver device.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $7.0 million, compared to $11.5 million in 2024
- Operating expenses decreased to $5.8 million in 2025 from $10.8 million in 2024
- Cash and cash equivalents totaled $762,000 as of December 31, 2025
- Company initiated a strategic alternatives review process to maximize shareholder value
- No revenue was generated in 2025
Financial Impact
Reduced net loss by $4.5 million year-over-year due to cost reductions, but no revenue generation and continued losses
Risk Factors
- Limited cash resources with only $762,000 in cash as of December 31, 2025
- History of significant losses and no revenue generation to date
- Uncertainty surrounding the strategic alternatives review process
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-037497 |
| Document: ea0284372-8k_endralife.htm | 0001213900-26-037497 |
| Document: 0001213900-26-037497-index-headers.html | 0001213900-26-037497 |
| Document: 0001213900-26-037497-index.html | 0001213900-26-037497 |
| Document: 0001213900-26-037497.txt | 0001213900-26-037497 |
| 8-K Data (Synthetic) | 0001213900-26-037497 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 425 | $4.82 | awaiting T+5 | — | $4.96 (+2.93%) |
Oct 8, 2026 19d ago | 3 | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 8, 2026 19d ago | SC 13D | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 1, 2026 26d ago | 425 | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Oct 1, 2026 26d ago | 8-K | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Sep 25, 2026 4w ago | 425 | $5.80 $6.31 | ▲ +8.79% | ▲ +7.59% | $4.96 (−14.47%) |
Sep 9, 2026 6w ago | 425 | $5.83 $5.13 | ▼ −12.01% | ▼ −11.67% | $4.96 (−14.91%) |
Aug 17, 2026 10w ago | 8-K | $4.51 $4.75 | ▲ +5.32% | ▲ +5.52% | $4.96 (+10.00%) |
Jul 17, 2026 14w ago | 425 | $4.99 $5.23 | ▲ +4.81% | ▲ +5.50% | $4.96 (−0.58%) |
Jul 9, 2026 15w ago | 8-K | $5.49 $5.27 | ▼ −4.01% | ▼ −3.88% | $4.96 (−9.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers